WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

Bayer

The Bayer GroupBayer is a global enterprise with core competencies in the fields of health care, agriculture and high-tech polymer materials. As an innovation company, it sets trends in research-intensive areas. Bayer's products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2014, the Group employed 118,900 people and had sales of EUR 42.2 billion. Capital expenditures amounted to EUR 2.5 billion, R&D expenses to EUR 3.6 billion.

www.bayer.com.

Bayer RSS Channel

Filters
List of articles in category Bayer
Title Published Date
Bayer announces publication of larotrectinib data in The New England Journal of Medicine 26 February 2018
FDA report reaffirms safety profile and effectiveness of Bayer's Xarelto® in routine clinical practice 16 January 2018
Bayer and Loxo Oncology to develop and commercialize two novel oncology therapies selectively targeting genetic drivers of cancer 17 November 2017
New scholarships worth EUR 417,000 awarded by Bayer Foundation to promote international talents 21 September 2017
Bayer's Rivaroxaban demonstrated superior protection against recurrent venous thromboembolism compared with Aspirin in EINSTEIN CHOICE study 23 March 2017
Another record year for Bayer - good progress with the acquisition of Monsanto 22 February 2017
Phase III COMPASS study with Bayer's rivaroxaban (Xarelto®) shows overwhelming efficacy and meets primary endpoint early 14 February 2017
Regorafenib granted priority review in the U.S. for second-line treatment of liver cancer 07 February 2017
Regorafenib from Bayer submitted to health authorities seeking approval in second-line treatment of liver cancer 09 November 2016
Bayer shows strong performance 26 October 2016
Bayer and CRISPR Therapeutics joint venture, named Casebia Therapeutics, establishes operations in Cambridge, MA 19 August 2016
Bayer Science & Education Foundation launches new round of funding 08 June 2016
Grants4Apps Accelerator 2016: You imagine, Bayer supports 10 May 2016
Bayer off to a successful start in 2016 26 April 2016
2016 Otto Bayer Award goes to Professor Dr. Dirk Trauner 25 April 2016
Bayer continues to grow its open innovation activities 09 February 2016
Bayer halves the price of its contraceptive implant Jadelle® for women in developing countries 08 January 2016
Bayer and CRISPR Therapeutics AG join forces to discover, develop and commercialize potential cures for serious genetic diseases 21 December 2015
Bayer's new five-year-contraceptive submitted for EU and US marketing authorization 20 November 2015
Bayer aligns organization with Life Science businesses 18 September 2015
  • Start
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • Next
  • End

Business & Industry

  • Pfizer to acquire Global Blood Therapeutics for $5.4 billion to enhance presence in rare hematology
  • Roche's subcutaneous formulation of Tecentriq demonstrates positive Phase III results
  • Bayer Consumer Health leaders propose new principles for science-led self-care
  • GSK signs agreement to support pandemic preparedness in Europe
  • Pfizer and BioNTech advance COVID-19 vaccine strategy with study start of next-generation vaccine candidate based on enhanced spike protein design

Research & Development

  • Scientists create long-acting injectable drug delivery system for tuberculosis
  • Treating cancer by sticking cells in place
  • Vitamin K prevents cell death: a new function for a long-known molecule
  • Disparities in United States COVID-19 vaccine distribution
  • New needle-free nasal vaccine shows promise for COVID-19
  • Scientists develop new biomimetic formulation for treating glioblastoma
  • SARS-CoV-2 hijacks nanotubes between neurons to infect them

Conferences & Events

  • New approach to treatment of deadly kidney cancer
  • SAE Media Group proudly presents the 2nd Annual Aseptic Processing Conference
  • Pharma join together to achieve new standards in digital and patient innovation for clinical transformation
  • SMi's 22nd Annual Pain Therapeutics Conference
  • SMi Group Introduces the 4th Annual Injectable Drug Delivery Conference 2022
  • SMi's 5th Annual Pharmaceutical Microbiology East Coast Conference
  • SMi's 3rd Annual AI in Drug Discovery Conference

Regulatory Affairs

  • FDA approves first systemic treatment for alopecia areata
  • FDA urges drug manufacturers to develop risk management plans to promote a dtronger, resilient drug supply chain
  • FDA limits use of Janssen COVID-19 vaccine to certain individuals
  • EMA establishes Cancer Medicines Forum with academia to optimise cancer treatments in clinical practice
  • FDA approves first generic of Symbicort to treat asthma and COPD
  1. You are here:  
  2. Home
  3. Bayer
  4. Bayer Consumer Health leaders propose new principles for science-led self-care

About

  • Home
  • Advertise
  • Privacy
  • Cookie Preferences
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2022. All Rights Reserved.